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By the low-stringency single-specific-primer PCR technique, a highly sensitive and rapid method for diag-
nosis of rifampin resistance in Mycobacterium tuberculosis was established. Seven rifampin-resistant and five
rifampin-susceptible specimens were analyzed. Rifampin resistance was determined by MIC measurement. A
complex electrophoretic pattern consisting of many bands was obtained for both susceptible and rifampin-
resistant isolates. The same pattern was obtained for all of the susceptible specimens, but differences between
resistant and susceptible isolates were found. DNA sequencing showed that a particular mutation produces a
specific electrophoretic pattern.
Tuberculosis has an extraordinary impact on the economies
of developing countries since the disease generally strikes in-
dividuals in their prime working years. Resistance of Mycobac-
terium tuberculosis to antituberculosis drugs is a conspicuously
large public health problem that has caused considerable dis-
tress in the involved community. As important as the treatment
of an infectious disease is correct diagnosis of the resistance of
the pathogen in the patient to be treated. Incorrect treatment
may turn the patient into a source of dissemination of a resis-
tant strain (6). Rifampin resistance is conferred by mutations
in the rpoB gene, which encodes the beta subunit of RNA
polymerase, an oligomeric enzyme responsible for RNA syn-
thesis (13, 14). Resistance in approximately 95% of rifampin-
resistant isolates is due to mutations in a 69-bp region of the
rpoB gene, corresponding to codons 511 to 533, making this a
good target for molecular genotypic diagnostic methods (11).
The mechanism of resistance in the remaining 5% is still un-
determined, with the exception of further mutations at codons
381 (8), 481 and 509 (5), and 505 (4) of the rpoB gene. Point
mutations within the 69-bp region of the rpoB gene involving
codons Ser-531, His-526, Gly-513, and Asp-516 have been
shown to lead to high-level resistance in Escherichia coli and M.
tuberculosis (2, 9, 10, 12, 13). Current methods for drug sus-
ceptibility testing of M. tuberculosis in primary specimens can
take up to 8 weeks. The rapid detection of drug-resistant M.
tuberculosis in clinical specimens by molecular techniques has
been tried (4, 5, 9, 10, 11, 12, 13) and may be a rational and
specific method to become popular in the future.
The low-stringency single-specific-primer PCR (LSSP-PCR)
is an extremely simple technique that permits detection of
single or multiple mutations in gene-sized DNA fragments (7).
Two PCR steps are necessary. The first is a specific PCR
(sPCR) to obtain the DNA template to be used in the second
one, the LSSP-PCR, which uses low-stringency conditions and
only one primer, usually one of the two primers used in the
sPCR. In this study, we used the LSSP-PCR to detect muta-
tions in the rpoB gene of M. tuberculosis isolates. We studied
seven rifampin-resistant and five rifampin-susceptible M. tu-
berculosis isolates, of which four were from the sputum of
patients in Minas Gerais, Brazil, with pulmonary tuberculosis
and one was susceptible reference strain H37Rv. MIC deter-
mination (3) was performed for all of the M. tuberculosis iso-
lates tested (0.06 to 64 g/ml) (Table 1). The sPCR was carried
out with primers RIF5 (GGCAACCGCCGCCTGCGTACG)
and RIF3 (GCGGTACGGCGTTTCGATGAA). These prim-
ers were established to encompass the entire codified protein
sequence (10) (GenBank accession number L05910). DNA
was extracted from isolates with Trizol reagent (Life Technol-
ogies) in accordance with the protocol of the manufacturer.
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TABLE 1. Rifampin MICs for the M. tuberculosis isolates used in
this study
Isolate MIC (g/ml) Phenotype
EB657 0.250 Susceptible
MO126 0.125 Susceptible
JU466a 0.125 Susceptible
LGP726 0.250 Susceptible
EFP041a 64 Resistant
AVF001 64 Resistant
ARJ254 64 Resistant
WSJ225 32 Resistant
IAS131a 64 Resistant
AGO247 32 Resistant
DES219 32 Resistant
a DNA was purified from cells cultivated for 3 or 4 weeks at 37°C in Lowen-
stein-Jensen medium. For the other isolates, DNA was extracted from cells
isolated from sputum.
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The reaction mixture consisted of 10 ng of purified mycobac-
terial DNA, 0.3 U of Taq DNA polymerase (Promega), 10
pmol of each primer, 200 M deoxynucleoside triphosphates,
50 mM KCl, 1.5 mM MgCl2, and 0.1% Triton X-100 in 10 mM
Tris-HCl buffer (pH 9.0) in a final volume of 10 l. This
reaction mixture was subjected to 30 cycles of amplification
consisting of 1 min each of denaturation at 94°C, annealing at
70°C, and elongation at 72°C. Reaction products were run in a
1% agarose gel stained with ethidium bromide, and the specific
432-bp band was excised from the gel and purified with the
QIAEX II gel extraction kit (Qiagen, Hilden, Germany). Prim-
ers RIF3 and RIF5 were tested in initial experiments for the
LSSP step. Primer RIF3 was selected for use because it showed
a major differentiation between resistance and susceptibility.
The LSSP-PCR was carried out with a volume of 10 l of 10
mM Tris-HCl (pH 9.0) containing 25 pmol of primer RIF3, 200
M deoxynucleoside triphosphates, 1.0 U of Taq polymerase
(Promega), 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100,
and 15 ng of template DNA obtained in the sPCR and purified
from agarose gel. Amplification was achieved with 39 cycles as
previously described (1). Products were analyzed by polyacryl-
amide gel electrophoresis and stained with silver salts (Fig. 1).
The same electrophoretic pattern was observed for all suscep-
tible isolates, but differences between rifampin-resistant and
-susceptible isolates were found. Alternatively, the 432-bp frag-
ment was cloned for sequencing. No mutation was detected in
the rpoB fragment from all of the sensitive isolates, whose
DNA sequence was identical to that previously published for
this fragment (10). DNA sequencing of resistant isolates
WSJ225, IAS131, and EFP041 confirmed mutations within the
69-bp region in codon 526 or 531 (Fig. 2 and Table 2). The
electrophoretic profiles of isolates IAS131 and EFP041 were
very similar, and their DNA sequences were identical. It seems
that a particular mutation gives a specific electrophoretic pat-
tern.
Taking into account that the subunits of RNA polymerase
are conserved among prokaryotes (2), our results, demonstrat-
ing electrophoretic pattern differences between the DNAs of
sensitive and rifampin-resistant isolates extracted directly from
sputum, make LSSP-PCR a very promising tool for the diag-
nosis of antituberculosis drug resistance. It seems that the
electrophoretic pattern, rather than band intensity, must be
considered to define differences between isolates. However,
attention must also be paid to band intensity since different
fragments similar in electrophoretic migration may occur. The
results obtained in our study must be validated with a great
number of rifampin-resistant isolates.
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